PRLD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Prelude Therapeutics Inc (PRLD) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company shows promising revenue growth, its financial performance is weighed down by significant losses and declining EPS. The technical indicators suggest a neutral to slightly bullish trend, but there are no strong trading signals or positive catalysts to justify an immediate buy decision. Holding off for now would be prudent.
The MACD is positive and expanding, indicating a bullish trend. The RSI is neutral at 60.214, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 2.301 and 2.431, with support levels at 1.881 and 1.752. Overall, the technical indicators suggest a mild bullish trend but not a strong buy signal.
Revenue growth of 116.67% YoY in Q3 2025 demonstrates strong top-line expansion. Gross margin remains at 100%, indicating operational efficiency.
Net income dropped by -38.88% YoY, and EPS declined by -39.53% YoY in Q3 2025, reflecting poor profitability. No recent news or significant trading trends from hedge funds, insiders, or Congress. The stock has a low chance of significant short-term price appreciation based on historical candlestick patterns.
In Q3 2025, revenue increased to $6.5M (+116.67% YoY), but net income dropped to -$19.73M (-38.88% YoY), and EPS declined to -0.26 (-39.53% YoY). Gross margin remained stable at 100%. The company is growing revenue but struggling with profitability.
No recent analyst ratings or price target changes are available for PRLD.
